Spinal Muscular Atrophy: From Approved Therapies to Future Therapeutic Targets for Personalized Medicine

Overview

Journal Cell Rep Med

Publisher Cell Press

Specialties Biology
General Medicine

Date 2021 Aug 2

PMID 34337562

Citations 56

Authors

Helena Chaytow

Kiterie M E Faller

Yu-Ting Huang

Thomas H Gillingwater

Affiliations

Soon will be listed here.

Abstract

Spinal muscular atrophy (SMA) is a devastating childhood motor neuron disease that, in the most severe cases and when left untreated, leads to death within the first two years of life. Recent therapeutic advances have given hope to families and patients by compensating for the deficiency in survival motor neuron (SMN) protein via gene therapy or other genetic manipulation. However, it is now apparent that none of these therapies will cure SMA alone. In this review, we discuss the three currently licensed therapies for SMA, briefly highlighting their respective advantages and disadvantages, before considering alternative approaches to increasing SMN protein levels. We then explore recent preclinical research that is identifying and targeting dysregulated pathways secondary to, or independent of, SMN deficiency that may provide adjunctive opportunities for SMA. These additional therapies are likely to be key for the development of treatments that are effective across the lifespan of SMA patients.

Citing Articles

Subacute liver injury in two young infants following gene replacement therapy for spinal muscular atrophy.

Ables C, Jaramillo C, Wood E, Stern S, Alashari M, Book L Mol Ther Methods Clin Dev. 2025; 32(3):101296.

PMID: 40017665 PMC: 11866129. DOI: 10.1016/j.omtm.2024.101296.

International Precision Child Health Partnership (IPCHiP): an initiative to accelerate discovery and improve outcomes in rare pediatric disease.

Howell K, White S, McTague A, DGama A, Costain G, Poduri A NPJ Genom Med. 2025; 10(1):13.

PMID: 40016282 PMC: 11868529. DOI: 10.1038/s41525-025-00474-8.

Skeletal Muscle Mitochondrial and Autophagic Dysregulation Are Modifiable in Spinal Muscular Atrophy.

Mikhail A, Ng S, Xhuti D, Lesinski M, Chhor J, Deguise M J Cachexia Sarcopenia Muscle. 2025; 16(1):e13701.

PMID: 39901351 PMC: 11790611. DOI: 10.1002/jcsm.13701.

Alterations in cardiac function correlate with a disruption in fatty acid metabolism in a mouse model of SMA.

Nair N, Kline R, Boyd I, Anikumar M, Thomson A, Lamont D Hum Mol Genet. 2025; 34(6):547-562.

PMID: 39810393 PMC: 11891873. DOI: 10.1093/hmg/ddaf006.

Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis.

Faller K, Chaytow H, Gillingwater T Nat Rev Neurol. 2025; 21(2):86-102.

PMID: 39743546 DOI: 10.1038/s41582-024-01049-4.

References

Chand D, Mohr F, McMillan H, Tukov F, Montgomery K, Kleyn A . Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2020; 74(3):560-566. DOI: 10.1016/j.jhep.2020.11.001. View

Boyd P, Tu W, Shorrock H, Groen E, Carter R, Powis R . Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy. PLoS Genet. 2017; 13(4):e1006744. PMC: 5417717. DOI: 10.1371/journal.pgen.1006744. View

Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl F, Raschke H, Blumcke I . Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet. 2003; 12(19):2481-9. DOI: 10.1093/hmg/ddg256. View

Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L . Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry. 2020; 91(11):1166-1174. DOI: 10.1136/jnnp-2020-323822. View

Foust K, Nurre E, Montgomery C, Hernandez A, Chan C, Kaspar B . Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2008; 27(1):59-65. PMC: 2895694. DOI: 10.1038/nbt.1515. View

Dangouloff T, Servais L . Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives. Ther Clin Risk Manag. 2019; 15:1153-1161. PMC: 6778729. DOI: 10.2147/TCRM.S172291. View

Powis R, Karyka E, Boyd P, Come J, Jones R, Zheng Y . Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy. JCI Insight. 2016; 1(11):e87908. PMC: 5033939. DOI: 10.1172/jci.insight.87908. View

Sturm S, Gunther A, Jaber B, Jordan P, Al Kotbi N, Parkar N . A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2018; 85(1):181-193. PMC: 6303280. DOI: 10.1111/bcp.13786. View

Merlini L, Solari A, Vita G, Bertini E, Minetti C, Mongini T . Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol. 2003; 18(8):537-41. DOI: 10.1177/08830738030180080501. View

10.

Ando S, Funato M, Ohuchi K, Inagaki S, Sato A, Seki J . The Protective Effects of Levetiracetam on a Human iPSCs-Derived Spinal Muscular Atrophy Model. Neurochem Res. 2019; 44(7):1773-1779. DOI: 10.1007/s11064-019-02814-4. View

11.

Tejero R, Balk S, Franco-Espin J, Ojeda J, Hennlein L, Drexl H . R-Roscovitine Improves Motoneuron Function in Mouse Models for Spinal Muscular Atrophy. iScience. 2020; 23(2):100826. PMC: 6992996. DOI: 10.1016/j.isci.2020.100826. View

12.

Verhaart I, Robertson A, Wilson I, Aartsma-Rus A, Cameron S, Jones C . Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017; 12(1):124. PMC: 5496354. DOI: 10.1186/s13023-017-0671-8. View

13.

Walter M, Wenninger S, Thiele S, Stauber J, Hiebeler M, Greckl E . Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study. J Neuromuscul Dis. 2019; 6(4):453-465. PMC: 6918909. DOI: 10.3233/JND-190416. View

14.

Valori C, Ning K, Wyles M, Mead R, Grierson A, Shaw P . Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med. 2010; 2(35):35ra42. DOI: 10.1126/scitranslmed.3000830. View

15.

De Vivo D, Bertini E, Swoboda K, Hwu W, Crawford T, Finkel R . Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019; 29(11):842-856. PMC: 7127286. DOI: 10.1016/j.nmd.2019.09.007. View

16.

Brahe C, Vitali T, Tiziano F, Angelozzi C, Pinto A, Borgo F . Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet. 2004; 13(2):256-9. DOI: 10.1038/sj.ejhg.5201320. View

17.

Houdebine L, DAmico D, Bastin J, Chali F, Desseille C, Rumeau V . Low-Intensity Running and High-Intensity Swimming Exercises Differentially Improve Energy Metabolism in Mice With Mild Spinal Muscular Atrophy. Front Physiol. 2019; 10:1258. PMC: 6781613. DOI: 10.3389/fphys.2019.01258. View

18.

Sergott R, Amorelli G, Baranello G, Barreau E, Beres S, Kane S . Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Ann Clin Transl Neurol. 2020; 8(1):54-65. PMC: 7818230. DOI: 10.1002/acn3.51239. View

19.

Stam M, Wadman R, Wijngaarde C, Bartels B, Asselman F, Otto L . Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial). BMJ Open. 2018; 8(7):e019932. PMC: 6067401. DOI: 10.1136/bmjopen-2017-019932. View

20.

Sumner C, Huynh T, Markowitz J, Perhac J, Hill B, Coovert D . Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol. 2003; 54(5):647-54. DOI: 10.1002/ana.10743. View